News | February 25, 2025
Teva and Sanofi present new outcome from Phase 2b study of duvakitug
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Subscribe To Our Newsletter & Stay Updated
